Skip to main content
Home

Language & Country Selector for Desktop

language-selector-globe Sandoz | en

Choose Location

  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Mexico | es
  • United States | en
  • Australia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Croatia | hr
  • Czech Republic | cs
  • Denmark | da
  • Finland | fi
  • France | fr
  • Germany | de
  • Hungary | hu
  • Italy | it
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Global | en
  • Sandoz | en
  • Saudi Arabia | ar
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Sandoz

Choose Location

Americas Asia Pacific Europe International Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Croatia | hr
  • Czech Republic | cs
  • Denmark | da
  • Finland | fi
  • France | fr
  • Germany | de
  • Hungary | hu
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Saudi Arabia | ar
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Turkey | tr
  • United Kingdom | en
  • United States | en
    • About Sandoz 
      • Our Purpose and Ambition 
      • What We Do 
      • Innovation, Quality and Supply 
      • Corporate Responsibility 
        • Ethics, Risk and Compliance 
        • Sandoz external funding 
        • Malaria Initiative 
        • Novartis Access 
        • World Child Cancer 
      • Our History 
      • Investor Information 
      A girl with a flower About Sandoz
    • Products & Services 
      • Disease Areas 
        • Anti-Infectives 
        • Respiratory 
        • Endocrinology 
        • Immunology 
        • Oncology 
      • Biopharmaceuticals 
        • Sandoz Biosimilars 
        • Sandoz Biosimilar Portfolio and Pipeline 
        • About Biologics 
        • Development of Biosimilars 
        • Information for Patients 
      • Prescription Medicines 
      • Over-The-Counter Medicines 
      • Partnerships and Collaborations 
        • Business to Business (B2B) 
        • Business to Business (B2B) 
        • Business to Business (B2B) 
      00181_300dpi_RGB Products & Services
    • People & Culture 
      • Sandoz Leadership 
        • Richard Saynor 
        • Francisco Ballester 
        • Martin Bischof 
        • Colin Bond 
        • Pierre Bourdage 
        • Valerie Chew 
        • Claire D'Abreu-Hayling 
        • Glenn A. Gerecke, PhD 
        • Rebecca Guntern 
        • Keren Haruvi 
        • Steffen Kurzawa 
        • Inge Maes 
        • Ingrid Sollerer 
      • Diversity & Inclusion 
      • Associate Stories 
    • Investors & Media 
      • Sandoz spin-off 
      • Media Releases 
      • Media Library 
      • Media Contacts 
      • Novartis Annual Reporting Suite 
    • Careers 
      • Working at Sandoz 
      • Diversity & Inclusion 
      • Associate Stories 
      • Job Search 
      Sandoz Careers Careers
    • News 
      • News Archive 
      • Media Releases 
      • Publications 
      • Stay Up-To-Date 
      A photo of people in a meeting hall News
    • Contacts 
    working at sandoz Home
  1. Home
  2. News
  3. All News
News Archive Navigation
  • All
  • Featured News
  • Media Release
icon
News Archive Navigation Language
  • English
  • French
  • German

January 2019

  • Media ReleaseJan 30, 2019
    Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
    Full year net sales up 5% (cc1, +6% USD) driven by strong performance of growth drivers: Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0 billion (+…
  • Media ReleaseJan 16, 2019
    Sandoz Inc. launches SYMJEPI™ (epinephrine) in the US
    Princeton, New Jersey, January 16, 2019 – Sandoz Inc. (Sandoz), a Novartis division, today announced the US market introduction of SYMJEPI™ (epinephrine) 0.3 mg Injection for the emergency treatment…
  • Media ReleaseJan 16, 2019
    Sandoz selects three finalists for Healthcare Access Challenge (Sandoz HACk) from over 400 global entries
    Competition generated ideas from more than 400 entrants in 80 countries – three shortlisted entrants from Uganda, the US and the Netherlands Three finalists shared innovative uses of artificial…
  • Media ReleaseJan 07, 2019
    Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder
    reSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder Cleared by the FDA in December, reSET-O is available immediately As part of a broader…

December 2018

  • Media ReleaseDec 19, 2018
    Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises
    Agreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart Over 400 million people worldwide have…
  • Media ReleaseDec 18, 2018
    Sandoz teams up to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
    Strategic collaboration agreement with Curetis subsidiary Ares Genetics to develop digital platform for development and life-cycle management of antibiotics Program will combine established…
  • Media ReleaseDec 10, 2018
    Sandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use Disorder
    reSET-OTM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder Pear Therapeutics is leading the development of a new therapeutic class with two FDA-…
  • Media ReleaseDec 04, 2018
    Sandoz certified Top Employer Asia Pacific 2019
    Sandoz has been certified by the Top Employers Institute for its exceptional employee offerings in Asia Pacific (APAC) The annual, international research undertaken by the Top Employers Institute…

November 2018

  • Media ReleaseNov 27, 2018
    Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)
    Biosimilar Ziextenzo® (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications1 Ziextenzo is indicated to…
  • Media ReleaseNov 20, 2018
    Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder
    reSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of…
  • Media ReleaseNov 07, 2018
    Sandoz commits to practical and scalable solutions to combat growing global threat of antimicrobial resistance (AMR)
    Antibiotics are the cornerstone of modern medicine, but AMR represents an increasingly serious threat to global public health1 Sandoz, as the world’s leading provider of high-quality antibiotics, is…
  • Media ReleaseNov 02, 2018
    Sandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needs
    Decision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is…

Pagination

  • ‹ Previous page
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • › Next page

Sandoz Global

Key resources
  • Patients & Caregivers
  • Job seekers
  • Investors
  • Media
Recent updates
  • Sandoz spin-off
Explore
  • Contacts
  • Locations
  • Biosimilar Portfolio and Pipeline
Sandoz Companies
  • 1A Pharma
  • Hexal
  • Lek
Footer Bottom
© 2023 Sandoz International GmbH
  • Terms of Use
  • Privacy Policy
  • About Cookies
  • Legal Notice
  • Social Media Community Guidelines
  • Cookie Settings
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for a global audience